Chemed Corp
NYSE:CHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (3.5), the stock would be worth $650.56 (54% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.3 | $421.11 |
0%
|
| 3-Year Average | 3.5 | $650.56 |
+54%
|
| 5-Year Average | 3.4 | $640.79 |
+52%
|
| Industry Average | 2.1 | $386.37 |
-8%
|
| Country Average | 3 | $567.78 |
+35%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$5.2B
|
/ |
Jan 2026
$2.5B
|
= |
|
|
$5.2B
|
/ |
Dec 2026
$2.7B
|
= |
|
|
$5.2B
|
/ |
Dec 2027
$2.9B
|
= |
|
|
$5.2B
|
/ |
Dec 2028
$3B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Chemed Corp
NYSE:CHE
|
5.8B USD | 2.3 | 21.8 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
99.1B USD | 0.4 | 56 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.7B EUR | 0.4 | 13.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.6B USD | 0 | 12.2 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 1.5 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 1.4 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD | 2.4 | 21.4 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD | 1.9 | 24.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.9 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.6B USD | 12.3 | -27.9 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 1.4 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
Chemed Corp
Glance View
Chemed Corporation, a somewhat enigmatic yet resolutely steadfast entity, operates in the realms of hospice care and plumbing services, a duality that intrigues analysts and investors alike. Established through strategic foresight, Chemed has crafted a remarkably resilient business model by housing two distinct subsidiaries under its corporate umbrella: VITAS Healthcare and Roto-Rooter. VITAS Healthcare, which still stands as the nation's largest provider of end-of-life care, dominates the hospice sector by offering comprehensive palliative care services right at the patients' doorstep, aiming to ensure dignity and comfort during life's final stages. This subsidiary capitalizes on a combination of Medicare and Medicaid reimbursements as well as private insurances, which form the backbone of its revenue stream. Meanwhile, Roto-Rooter, a company with a name synonymous with plumbing repair and maintenance, fortifies Chemed's revenue streams through an entirely different channel. Known as a household name across America, Roto-Rooter offers an extensive range of services from emergency plumbing repair to water cleanup and restoration. With its franchise model combined with company-operated branches, Roto-Rooter generates income primarily through service fees. The dual nature of Chemed’s operational style—a blend of healthcare sensitivity and industrial pragmatism—not only ensures diversified income avenues but also exemplifies a pragmatic approach to risk management. This business strategy, deftly combining distinct yet robust sectors, allows Chemed to weather economic fluctuations that might impact one industry but not the other, ultimately creating a stable financial foundation for the company.